Journal article icon

Journal article

Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence.

Abstract:

Recombinant plasmid DNA and attenuated poxviruses are under development as cancer and infectious disease vaccines. We present the results of a phase I clinical trial of recombinant plasmid DNA and modified vaccinia Ankara (MVA), both encoding 7 melanoma tumor antigen cytotoxic T lymphocyte (CTL) epitopes. HLA-A*0201-positive patients with surgically treated melanoma received either a "prime-boost" DNA/MVA or a homologous MVA-only regimen. Ex vivo tetramer analysis, performed at multiple time ...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1002/ijc.20569

Authors


Expand authors...
Journal:
International journal of cancer. Journal international du cancer
Volume:
113
Issue:
2
Pages:
259-266
Publication date:
2005-01-05
DOI:
EISSN:
1097-0215
ISSN:
0020-7136
URN:
uuid:59fc61da-d5a6-404f-97aa-67ad942dbd8b
Source identifiers:
32850
Local pid:
pubs:32850

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP